Evidence map›Paper›PMID 27389080›Full record

ArticleJournal of neurology2016

Cerebral microbleeds in early Alzheimer's disease.

T Poliakova, O Levin, A Arablinskiy, E Vasenina, I Zerr

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Risk of Alzheimer's disease in Down syndrome: Insights gained by multi-omics.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. [Relationship between Oral Microbiota and Alzheimer's Disease].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Basal lamina changes in neurodegenerative disorders.Molecular neurodegeneration · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

T PoliakovaRussian Medical Academy of Postgraduate Education, Moscow, Russia.
O LevinRussian Medical Academy of Postgraduate Education, Moscow, Russia.
A ArablinskiyClinical Hospital of S.P. Botkin, Moscow, Russia.
E VaseninaRussian Medical Academy of Postgraduate Education, Moscow, Russia.
I ZerrDepartment of Neurology, National Reference Center for Neurodegenerative Diseases, University Medical School, Georg-August-Universität Göttingen, Robert-Koch Str. 40, 37075, Göttingen, Germany. epicjd@med.uni-goettingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We hypothesize that cerebral microbleeds (CMB) in patients with different neuropsychological profiles (amnestic or non-amnestic) and MRI features of vascular damage could provide important information on the underlying pathological process in early Alzheimer's disease. The study was performed at two trial sites. We studied 136 outpatients with cognitive decline. MRI was performed using a magnetic field of 1.5 and 3 T. Neuropsychological assessment included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment scale (MoCA), Addenbrooke's Cognitive Examination (ACE-R), Cambridge Cognitive Examination battery (CAMCOG) (Part 3), Clock Drawing Test, fluency test and the visual memory test (SCT). CSF was examined for standard parameters such as tau, phosphorylated tau, amyloid-β 1-40 and 42 and Qalbumin, in accordance with established protocols and genotype. In 61 patients (45 %), at least 1 CMB was found. Most of the CMBs were described in the amnestic profile (67 %). In 86 % of the cases, multiple CMB were observed. The ratio of Aβ1-40/42 in non-amnestic patients with CMB was significantly lower (mean 0.6) than in patients without CMB (mean 1.2). A notable difference in the albumin ratio as an indicator of the BBB was observed between groups with and without CMB. In the CMP-positive group, the E2 genotype was observed more frequently, and the E4 genotype less frequently, than in the CMB-negative group. Based on the cerebrospinal fluid-serum albumin ratio, we were able to show that patients with CMB present several features of BBB dysfunction. According to logistic regression, the predictive factors for CMB in patients with cognitive decline were age, WMHs score and albumin ratio. We found a significant reduction in the Aβ-amyloid ratio in the non-amnestic profile group with CMB (particularly in the cortical region) in comparison to those without CMB. While this is an interesting finding, its significance needs to be assessed in a prospective follow-up.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesApolipoproteins ECerebral HemorrhageFemaleHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMental Status ScheduleMiddle AgedNeuropsychological TestsPeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (11-42)Apolipoproteins EPeptide Fragmentstau ProteinsAlzheimer diseaseBlood–brain barrier damageCerebral microbleedsMagnetic resonance imagingMild cognitive impairmentWhite matter lesions

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.